Clinical Trials
4
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Jonathan Brammer
- Target Recruit Count
- 28
- Registration Number
- NCT05592015
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Phase 1
Recruiting
- Conditions
- T-Cell Large Granular Lymphocyte Leukemia
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Jonathan Brammer
- Target Recruit Count
- 27
- Registration Number
- NCT05141682
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Phase 1
Recruiting
- Conditions
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/LymphomaRecurrent Adult T-Cell Leukemia/LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- John Reneau
- Target Recruit Count
- 12
- Registration Number
- NCT04848064
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Phase 2
Completed
- Conditions
- Primary Cutaneous Anaplastic Large Cell LymphomaStage III Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage I Cutaneous T-Cell Non-Hodgkin LymphomaLymphomatoid PapulosisStage IV Cutaneous T-Cell Non-Hodgkin LymphomaStage II Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- John Reneau
- Target Recruit Count
- 26
- Registration Number
- NCT03409432
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
News
No news found